Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs BridgeBio Pharma Inc (BBIO) Price & Performance

AMC ENTERTAINMENT HOLDINGS, INC.Trade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

AMC ENTERTAINMENT HOLDINGS, INC. vs BridgeBio Pharma Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.41 (market cap $2.16B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 7.7× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

AMCBBIO
Market Cap
$2.16B$16.61B
Sector
MediaHealth
52-Week High
$3.15$90.17
52-Week Low
$0.95$47.29
Enterprise Value
$9.10B$18.16B
Dividend Yield
0.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMC ENTERTAINMENT HOLDINGS, INC.

AMC trades at $2.59, up 0.78% today, with a bullish technical signal and recent earnings beats. The stock is testing the $3.00 resistance level, supported by record box office performance and improved cash flow trends. However, the company remains unprofitable with a net income margin of -10.59% and high debt levels, though valuation ratios like P/S of 0.28 and P/B of 0.64 suggest potential undervaluation.

Outlook is cautiously optimistic due to strong revenue growth and cost discipline, but risks include persistent losses and heavy debt burden. Analyst consensus price target is $3.00, with 32% buy ratings, indicating moderate upside potential if operational improvements continue.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMC ENTERTAINMENT HOLDINGS, INC.

AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.

Read more on AMC

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO